ASX:RAC

Race Oncology Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume76,322 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive RAC News and Ratings via Email

Sign-up to receive the latest news and ratings for Race Oncology and its competitors with MarketBeat's FREE daily newsletter.

About Race Oncology

Race Oncology Limited operates as a specialty pharmaceutical company in Australia. The company is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. It has a preclinical research program with the University of Newcastle to explore the use of Bisantrene to treat melanoma. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.

Why is the Race Oncology (ASX:RAC) share price up 18% in a month?
September 23, 2021 | msn.com

Moderna’s R&D Day Indicates Covid-19 Will Remain The Biggest Driver Of The Stock
September 14, 2021 | forbes.com

Insider Selling: Race Oncology Limited (ASX:RAC) Insider Sells 61,745 Shares of Stock
September 7, 2021 | americanbankingnews.com

Diversity Leaders in Business Awards 2021: Keya Watkins, Catalyst Clinical Research LLC
August 27, 2021 | bizjournals.com

The new blood test promising to detect a variety of cancers
August 23, 2021 | msn.com

Chicago Oncology Nurse Diagnosed With Stage 4 Cancer Focuses On Positive, Raising Money For Research
August 20, 2021 | msn.com

What’s going on with the Race Oncology (ASX:RAC) share price today?
August 8, 2021 | msn.com

Coherus BioSciences, inc (CHRS) Q2 2021 Earnings Call Transcript
August 6, 2021 | msn.com

Dog seriously injured after walking into man-made trap in Shropshire woods
August 4, 2021 | msn.com

What's New With Moderna Stock?
August 4, 2021 | nasdaq.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:RAC
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.raceoncology.com
Phone61 3 9097 1656
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$387,385.00
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow24.29
Book ValueA$0.10 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.21 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Race Oncology.

4.4 Community Rank

Outperform Votes
Race Oncology has received 19 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Race Oncology has received 10 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Race Oncology has received 65.52% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Race Oncology and other stocks. Vote “Outperform” if you believe RAC will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RAC will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Race Oncology does not currently pay a dividend.
Dividend Growth
Race Oncology does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Race Oncology insiders have bought 7.70% more of their company's stock than they have sold. Specifically, they have bought A$207,620.00 in company stock and sold A$192,768.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Race Oncology (ASX:RAC) Frequently Asked Questions

What stocks does MarketBeat like better than Race Oncology?

Wall Street analysts have given Race Oncology a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Race Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Race Oncology's earnings last quarter?

Race Oncology Limited (ASX:RAC) announced its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter.
View Race Oncology's earnings history.

Who are Race Oncology's key executives?

Race Oncology's management team includes the following people:

Mr. Phillip R. Lynch, CEO, MD & Director
Dr. Daniel Tillett, Chief Scientific Officer & Exec. Director
Prof. Borje S. Andersson, Chairman of Clinical Advisory Board & Chief Medical Officer
Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 58)

Who are some of Race Oncology's key competitors?

Some companies that are related to Race Oncology include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of RAC's competitors.

What other stocks do shareholders of Race Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Race Oncology investors own include Mesoblast (MESO), Pilbara Minerals (PLS) and Mount Gibson Iron (MGX).

What is Race Oncology's stock symbol?

Race Oncology trades on the ASX under the ticker symbol "RAC."

How much money does Race Oncology make?

Race Oncology has a market capitalization of $0.00 and generates $387,385.00 in revenue each year.

What is Race Oncology's official website?

The official website for Race Oncology is www.raceoncology.com.

How can I contact Race Oncology?

The company can be reached via phone at 61 3 9097 1656.

This page was last updated on 9/23/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.